RecruitingPhase 3NCT04563520

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Studying Hemophilia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Emory University
Principal Investigator
Robert Sidonio, MD
Emory University
Intervention
Emicizumab(drug)
Enrollment
5 enrolled
Eligibility
6 years · All sexes
Timeline
20262027

Study locations (2)

Collaborators

Takeda Pharmaceuticals North America, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04563520 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia

← Back to all trials